SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American ...
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
Stay updated with breaking news from Springwork Annual Report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...
– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of B...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifiraf...